How have NRSNW shares performed in 2024?

NeuroSense Therapeutics' stock was trading at $0.0781 on January 1st, 2024. Since then, NRSNW shares have increased by 220.1% and is now trading at $0.25. View the best growth stocks for 2024 here .

Are investors shorting NeuroSense Therapeutics?

NeuroSense Therapeutics saw a drop in short interest in March. As of March 31st, there was short interest totaling 1,800 shares, a drop of 57.1% from the March 15th total of 4,200 shares. Based on an average daily volume of 10,000 shares, the short-interest ratio is currently 0.2 days. View NeuroSense Therapeutics' Short Interest .

How do I buy shares of NeuroSense Therapeutics?

Shares of NRSNW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:NRSNW

NeuroSense Therapeutics (NRSNW) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free NRSNW Stock Alerts

$0.25

0.00 (0.00%)

(As of 04/19/2024 ET)

Compare

Today's Range: $0.25
▼
$0.25
50-Day Range: $0.20
▼
$0.55
52-Week Range: $0.07
▼
$0.65

Volume: N/A
Average Volume: 11,068 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Competitors Financials SEC Filings Short Interest Social Media

Get NeuroSense Therapeutics alerts:

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About NeuroSense Therapeutics

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. Its lead product is PrimeC, an extended-release oral formulation of a fixed dose combination of ciprofloxacin and celecoxib for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.

NRSNW Stock Price History

30 days | 90 days | 365 days | Advanced Chart

NRSNW Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com

Receive NRSNW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuroSense Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:NRSNW
CUSIP: N/A
CIK: 1875091
Web: N/A
Phone: 972-9-799-6183
Fax: N/A
Employees: 14
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Mr. Alon Ben-Noon (Age 45)
Co-Founder, CEO & Director
Comp: $619k
Mr. Or Eisenberg (Age 43)
Chief Financial Officer
Comp: $378k
Dr. Ferenc Tracik M.D. (Age 60)
Chief Medical Officer
Comp: $513k
Ms. Hagit Binder (Age 46)
Chief Operation Officer
Dr. Niva Russek-Blum Ph.D. (Age 45)
Chief Technology Officer
Ms. Yael Barak (Age 54)
VP of Quality & Compliance
Ms. Keren Pushett
Head of HR
Mr. Eidan Loushi
C.R.A.

Key Competitors

View All Competitors

NRSNW Stock Analysis - Frequently Asked Questions

How have NRSNW shares performed in 2024?: NeuroSense Therapeutics' stock was trading at $0.0781 on January 1st, 2024. Since then, NRSNW shares have increased by 220.1% and is now trading at $0.25.
View the best growth stocks for 2024 here.
Are investors shorting NeuroSense Therapeutics?: NeuroSense Therapeutics saw a drop in short interest in March. As of March 31st, there was short interest totaling 1,800 shares, a drop of 57.1% from the March 15th total of 4,200 shares. Based on an average daily volume of 10,000 shares, the short-interest ratio is currently 0.2 days.
View NeuroSense Therapeutics' Short Interest.
How do I buy shares of NeuroSense Therapeutics?: Shares of NRSNW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NRSNW) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial